Cutaneous Leishmaniasis, American
6
0
0
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (6)
Pilot Study: Miltefosine Gel (G-MTF) in Patients With Cutaneous Leishmaniasis
Treatment of Cutaneous Leishmaniasis With Liposomal Amphotericin B in the Elderly
Tofacitinib Associated With Meglumine Antimoniate in Cutaneous Leishmaniasis
Topical Sm29 in Combination With Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis.
Feasibility and Usability of Mobile Applications for Monitoring Cutaneous Leishmaniasis Treatment in Colombia
Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis